[1]崔 磊,陈 楠,颜 琳,等.培土生金方治疗肺部多重耐药菌感染疗效研究[J].陕西中医,2023,(8):1082-1085.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.019]
　CUI Lei,CHEN Nan,YAN Lin,et al.Study on the therapeutic effect of Peitu Shengjin prescription on pulmonary multidrug-resistant bacterial infection[J].,2023,(8):1082-1085.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.019]
点击复制

培土生金方治疗肺部多重耐药菌感染疗效研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2023年8期
页码:
1082-1085
栏目:
临床研究
出版日期:
2023-08-05

文章信息/Info

Title:
Study on the therapeutic effect of Peitu Shengjin prescription on pulmonary multidrug-resistant bacterial infection
作者:
崔 磊; 陈 楠; 颜 琳; 武加秀; 仲 洁
(济宁市中医院重症医学科,山东 济宁 272004)
Author(s):
CUI Lei; CHEN Nan; YAN Lin; WU Jiaxiu; ZHONG Jie
(Department of Intensive Care Medicine,Jining Hospital of Traditional Chinese Medicine,Jining 272004,China)
关键词:
肺部多重耐药菌感染;  培土生金方;  炎症级联反应;  免疫功能;  氧代谢;  肺功能
Keywords:
ulmonary multidrug-resistant bacterial infection;  Peitu Shengjin prescription;  Inflammatory cascade;  Immune function;  Oxygen metabolism;  Lung function
分类号:
R 259
DOI:
DOI:10.3969/j.issn.1000-7369.2023.08.019
文献标志码:
A
摘要:
目的:观察培土生金方治疗肺部多重耐药菌感染患者疗效及对白细胞(WBC)计数、降钙素原(PCT)、血乳酸(LAC)水平的影响。方法:选择肺部多重耐药菌感染患者60例,以随机数字表法分为两组,每组30例,对照组给予基础对症治疗,研究组在对照组基础上给予培土生金方治疗。治疗前、后检测两组患者WBC、PCT、LAC、动脉血氧分压(PaO2)、氧合指数(PaO2/FiO2)水平和临床肺部感染评分(CPIS),记录患者细菌清除率、肺部炎症明显吸收时间、退热时间、机械通气时间,比较两组患者临床疗效、不良反应。结果:治疗后,研究组WBC、PCT、LAC含量低于对照组,PaO2、PaO2/FiO2高于对照组(均P<0.05)。治疗后,研究组患者CPIS评分低于对照组(P<0.05)。研究组细菌清除率高于对照组,肺部炎症明显吸收时间、退热时间、机械通气时间较对照组短(均P<0.05)。研究组患者总有效率显著高于对照组(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:培土生金方治疗肺部多重耐药菌感染患者,可抑制炎症级联反应,改善血气指标、氧代谢及肺功能,促进清除细菌,改善临床症状,提升临床疗效。
Abstract:
Objective:To observe the therapeutic effect of Peitu Shengjin prescription in the treatment of pulmonary multidrug-resistant bacteria infection and its influence on the count of white blood cells(WBC),procalcitonin(PCT)and blood lactic acid(LAC).Methods:Sixty patients with pulmonary multidrug-resistant bacteria infection were selected and divided into two groups by random number table method,with 30 patients in each group.The control group was given basic symptomatic treatment,and the study group was given Peitu Shengjin prescription on the basis of the control group.Before and after treatment,WBC,PCT,LAC,arterial partial oxygen pressure(PaO2)and oxygenation index(PaO2/FiO2)of the two groups were detected.Clinical pulmonary infection(CPIS)of the patients were evaluated.Bacterial clearance rate,obvious absorption time of pulmonary inflammation,fever reduction time and mechanical ventilation time of the patients were recorded.The clinical efficacy and adverse reactions were compared between the treatment group and the control group.Results:After treatment,the contents of WBC,PCT and LAC in the study group were lower than those in the control group,while the contents of PaO2 and PaO2/FiO2 were higher than those in the control group(all P<0.05).After treatment,CPIS score in the study group was lower than that in the control group(P<0.05).The bacterial clearance rate of the study group was higher than that of the control group,and the obvious absorption time of pulmonary inflammation,fever reduction time and mechanical ventilation time were lower than those of the control group(all P<0.05).After treatment,the total effective rate of the study group was significantly higher than that of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:In the treatment of patients with pulmonary multidrug-resistant bacterial infection,Peitu Shengjin prescription can inhibit the inflammatory cascade,improve blood gas indexes,oxygen metabolism and lung function,promote the removal of bacteria,improve clinical symptoms,and enhance clinical efficacy.

参考文献/References:

[1] 崔 磊,辛显波,申 斌,等.中药雾化吸入联合保留灌肠对多重耐药菌所致脓毒症(气分实热证)的临床研究[J].中国医院用药评价与分析,2021,21(6):682-686.
[2] 张 娜,冷建春.人参败毒散加减联合西药治疗重症肺炎患者多重耐药菌感染的临床效果[J].中国医药,2023,18(4):583-587.
[3] 周召武,罗小星.通阳泄浊方对老年脑病合并肺部多重耐药菌感染患者细胞因子、血清肺表面活性蛋白、内皮功能和免疫抑制的影响[J].中医学报,2021,36(5):1078-1083.
[4] 王 玲.中医益气健脾清热化痰法治疗脑梗死后多重耐药铜绿假单胞菌肺部感染的临床观察[J].现代中西医结合杂志,2019,28(1):56-59.
[5] 彭炳贤,罗子清,张 溪.白虎加人参汤联合复方薤白胶囊治疗重症肺部感染疗效研究[J].陕西中医,2021,42(12):1692-1695.
[6] 中华医学会呼吸病学分会.社区获得性肺炎诊断和治疗指南[J].中华结核和呼吸杂志,2006,29(10):651-655.
[7] 中华医学会呼吸病学分会.医院获得性肺炎诊断和治疗指南(草案)[J].中华结核和呼吸杂志,1999,22(4):8-10.
[8] 中华人民共和国卫生部.多重耐药菌医院感染预防与控制技术指南(试行)[J].药物不良反应杂志,2011,13(2):108-109.
[9] 国家食品药品监督管理总局.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版,2002:73-77.
[10] 庞天义,满德强,常 群.老年肺部感染住院患者合并多重耐药菌感染的危险因素探讨及风险Nomogram模型的建立[J].中国抗生素杂志,2021,46(12):1157-1160,封3.
[11] Agarwal N,Agarwal SK,Bhattacharya S,et al.Antibiotic prophylaxis for breast oncosurgery in a setting with a high prevalence of multidrug-resistant bacteria:Common sense infection control measures are more important than prolonged antibiotics[J].Infection Control and Hospital Epidemiology,2018,39(4):498-500.
[12] Takada H,Hifumi T,Nishimoto N,et al.Linezolid versus vancomycin for nosocomial pneumonia due to methicillin-resistant staphylococcus aureus in the elderly:A retrospective cohort analysis effectiveness of linezolid in the elderly[J].The American Journal of Emergency Medicine,2017,35(2):245-248.
[13] Wieland K,Chhatwal P,Vonberg RP,et al.Nosocomial outbreaks caused by acinetobacter baumannii and pseudomonas aeruginosa:Results of a systematic review[J].American Journal of Infection Control,2018,46(6):643-648.
[14] 马颖欣,张国平,乔安邦,等.老年肺癌患者术后发生院内肺部感染的病原菌分布及多重耐药性分析[J].传染病信息,2020,33(2):147-150.
[15] 丁 娜,远 颖,赵润芬.玉屏风散对慢性阻塞性肺疾病急性加重及细胞免疫失衡的调节作用[J].天津中医药,2022,39(4):443-449.
[16] 樊 宇,张轶博.角质细胞生长因子-2在金黄色葡萄球菌所致肺部感染中的作用及机制研究[J].陕西医学杂志,2021,50(12):1482-1486.
[17] 林燕林,张星星,高志凌,等.清热化痰法联合亚胺培南-西司他丁钠对重症肺部感染患者IL-6、TNF-α水平的影响[J].陕西中医,2020,41(7):891-893.
[18] 胡秋利,崔 磊,刘长伟.培土生金法干预肺部多重耐药菌感染的疗效观察[J].中国中医基础医学杂志,2017,23(12):1728-1730.
[19] 王笑妍,李 玫,沈志纲,等.红景天苷药理作用研究进展[J].中成药,2022,44(12):3932-3935.
[20] 迟宇昊,李 暘,申 远.麦冬化学成分及药理作用研究进展[J].新乡医学院学报,2021,38(2):189-192.
[21] 韩 凡,钟国富,叶 烨,等.老年病毒合并细菌性肺炎的临床特征及影响因素分析[J].中国医药导报,2020,17(8):129-133,143.

备注/Memo

备注/Memo:
基金项目:山东省中医药科技项目(2021M081)
更新日期/Last Update: 2023-08-10